Iowa is currently home to 796 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Iowa City, Des Moines, Sioux City and West Des Moines. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma
NCT05987332
Recruiting
This is a Phase 2/3, multi-arm, multi-stage, open-label study of human leukocyte antigen (HLA)-A\*02:01 negative participants with metastatic uveal melanoma (MUM) who will be randomized to receive either IDE196 + crizotinib or investigator's choice of treatment (pembrolizumab, ipilimumab + nivolumab, or dacarbazine).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/05/2025
Locations: University of Iowa, Iowa City, Iowa
Conditions: Metastatic Uveal Melanoma
Register for Updates
The THOR IDE Study
NCT05916950
Recruiting
The goal of this clinical trial is to test the Thor system in adult (≥ 18 year old) patients with de novo (new, never treated) calcified lesions in infrainguinal (leg) arteries (peripheral artery disease or PAD). The main question\[s\] it aims to answer are: * Is the Thor system safe in treating these lesions * Does the Thor system work to treat these lesions Participants will: * Receive treatment with the Thor system * Have follow-up visits at Discharge, 30 days, 6 months, and 12 months
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/05/2025
Locations: Vascular Institute of the Midwest, Davenport, Iowa
Conditions: Peripheral Artery Disease, Peripheral Artery Stenosis, Peripheral Artery Calcification, PAD
Register for Updates
Assessment of Combined CCM and ICD Device in HFrEF
NCT05855135
Recruiting
The goal of this clinical trial is to demonstrate that the OPTIMIZER® Integra CCM-D System (the "CCM-D System") can safely and effective convert induced ventricular fibrillation (VF) and spontaneous ventricular tachycardia and/or ventricular fibrillation (VT/VF) episodes in subjects with Stage C or D heart failure who remain symptomatic despite being on guideline-directed medical therapy (GDMT), are not indicated for cardiac resynchronization therapy (CRT), and have heart failure with reduced le... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/05/2025
Locations: Iowa Heart Center, West Des Moines, Iowa
Conditions: Heart Failure, Heart Failure With Reduced Ejection Fraction, Implantable Defibrillator User, CCM Therapy, Non-ischemic Cardiomyopathy, Ischemic Cardiomyopathy, Sudden Cardiac Arrest, Arrhythmias, Cardiac, Ventricular Tachycardia, Ventricular Fibrillation
Register for Updates
A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma
NCT05675449
Recruiting
The main purpose of the study is to evaluate the safety and tolerability of the combination of elranatamab and carfilzomib and dexamethasone or elranatamab and maplirpacept. There are 2 parts to this study. Part 1 will evaluate the safety and tolerability of elranatamab when given in combination with carfilzomib plus dexamethasone. Part 2 has 2 arms. The first will evaluate the safety and tolerability of elranatamab when given in combination with maplirpacept. The second will identify the optim... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/05/2025
Locations: University of Iowa Hospitals and Clinics, Iowa City, Iowa
Conditions: Multiple Myeloma
Register for Updates
ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)
NCT05580562
Recruiting
This is a randomized, double-blind, placebo-controlled, parallel-group, international, Phase 3 study in patients with newly diagnosed H3 K27M-mutant diffuse glioma to assess whether treatment with ONC201 following frontline radiotherapy will extend overall survival and progression-free survival in this population. Eligible participants will have histologically diagnosed H3 K27M-mutant diffuse glioma and have completed standard frontline radiotherapy.
Gender:
ALL
Ages:
All
Trial Updated:
06/05/2025
Locations: University of Iowa Hospitals & Clinics, Iowa City, Iowa
Conditions: H3 K27M, Glioma
Register for Updates
Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)
NCT05564403
Recruiting
This phase II ComboMATCH treatment trial compares the usual treatment of modified leucovorin, fluorouracil and oxaliplatin (mFOLFOX6) chemotherapy to using binimetinib plus mFOLFOX6 chemotherapy to shrink tumors in patients with biliary tract cancers that have spread to other places in the body (advanced) and had progression of cancer after previous treatments (2nd line setting). Fluorouracil is in a class of medications called antimetabolites. It works by slowing or stopping the growth of cance... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/05/2025
Locations: UI Health Care Mission Cancer and Blood - Ankeny Clinic, Ankeny, Iowa
Conditions: Recurrent Biliary Tract Carcinoma, Recurrent Gallbladder Carcinoma, Recurrent Intrahepatic Cholangiocarcinoma, Stage III Distal Bile Duct Cancer AJCC v8, Stage III Hilar Cholangiocarcinoma AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Distal Bile Duct Cancer AJCC v8, Stage IV Hilar Cholangiocarcinoma AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8, Unresectable Biliary Tract Carcinoma, Unresectable Gallbladder Carcinoma, Unresectable Intrahepatic Cholangiocarcinoma, Advanced Biliary Tract Carcinoma, Advanced Gallbladder Carcinoma, Advanced Intrahepatic Cholangiocarcinoma, Stage III Gallbladder Cancer AJCC v8, Stage IV Gallbladder Cancer AJCC v8
Register for Updates
Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
NCT05407636
Recruiting
ABBV-RGX-314 (also known as RGX-314) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD). Wet AMD is characterized by loss of vision due to new, leaky blood vessel formation in the retina. Wet AMD is a significant cause of vision loss in the United States, Europe and Japan, with up to 2 million people living with wet AMD in these geographies alone. Current anti-vascular endothelial growth factor (VEGF) therapies ha... Read More
Gender:
ALL
Ages:
Between 50 years and 89 years
Trial Updated:
06/05/2025
Locations: Wolfe Eye Clinic, West Des Moines, Iowa
Conditions: AMD, nAMD, Wet Age-related Macular Degeneration, wAMD, WetAMD, CNV
Register for Updates
JAGUAR Trial: ObJective Analysis to GaUge EVAR Outcomes Through Randomization
NCT05064540
Recruiting
Prospective, randomized, multi-center study designed to evaluate the outcomes of commercially available contemporary EVAR in a real-world population. Patients will be randomized into two device cohorts and compared across the primary endpoints. Patients will be followed procedurally to discharge, at 1, 6, 12 months and annually through to 5 years (total follow-up commitment).
Gender:
ALL
Ages:
21 years and above
Trial Updated:
06/05/2025
Locations: University of Iowa Hospitals and Clinics, Iowa City, Iowa
Conditions: AAA, AAA - Abdominal Aortic Aneurysm
Register for Updates
Catheter-Related Early Thromboprophylaxis With Enoxaparin Studies
NCT04924322
Recruiting
The goal of the CRETE Studies is to investigate the newly identified age-dependent heterogeneity in the efficacy of enoxaparin in reducing the risk of central venous catheter-associated deep venous thrombosis in critically ill children.
Gender:
ALL
Ages:
17 years and below
Trial Updated:
06/05/2025
Locations: Stead Family Children's Hospital, Iowa City, Iowa
Conditions: Deep Venous Thrombosis
Register for Updates
Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer
NCT04699838
Recruiting
The primary objective of this single arm study is to estimate the progression free survival of previously-untreated patients with extensive stage small cell lung cancer. Patients will receive initial chemo-immunotherapy followed by maintenance therapy with durvalumab and oral ceralasertib.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/05/2025
Locations: University of Iowa Hospitals and Clinics, Iowa City, Iowa
Conditions: Extensive Stage Small Cell Lung Cancer
Register for Updates
A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma
NCT03871257
Recruiting
This phase III trial studies if selumetinib works just as well as the standard treatment with carboplatin/vincristine (CV) for subjects with NF1-associated low grade glioma (LGG), and to see if selumetinib is better than CV in improving vision in subjects with LGG of the optic pathway (vision nerves). Selumetinib is a drug that works by blocking some enzymes that low-grade glioma tumor cells need for their growth. This results in killing tumor cells. Drugs used as chemotherapy, such as carboplat... Read More
Gender:
ALL
Ages:
Between 2 years and 21 years
Trial Updated:
06/05/2025
Locations: Blank Children's Hospital, Des Moines, Iowa
Conditions: Low Grade Glioma, Neurofibromatosis Type 1, Visual Pathway Glioma
Register for Updates
Chronic Venous Thrombosis: Relief With Adjunctive Catheter-Directed Therapy (The C-TRACT Trial)
NCT03250247
Recruiting
The purpose of this study is to determine if the use of image-guided, endovascular therapy (EVT) is an effective strategy with which to reduce Post Thrombotic Syndrome (PTS) disease severity and improve quality of life in patients with established disabling iliac-obstructive post thrombotic syndrome (DIO-PTS).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/05/2025
Locations: University of Iowa, Iowa City, Iowa
Conditions: Deep Vein Thrombosis, Venous Stasis, Venous Insufficiency, Venous Leg Ulcer, Venous Reflux, Post Thrombotic Syndrome
Register for Updates